单位：[1]Union Hospital, Tongji Medical College, Huazhong University ofScience and Technology, Wuhan, Hubei, China华中科技大学同济医学院附属协和医院[2]Huazhong University of Science and Technology Union ShenzhenHospital, Guangdong Medical University, Shenzhen, Guangdong,China[3]Yi Chang Central People’s Hospital, The First College of ClinicalMedical Science, China Three Gorges University, Yichang, Hubei,China[4]Xiangyang Central Hospital, The Affiliated Hospital of HubeiUniversity of Arts and Science, Xiangyang, Hubei, China[5]Suizhou Hospital, Hubei Univercity of Medicine, Suizhou, Hubei,China[6]Centre for Haematology Research, Department of Immunology andInflammation, Imperial College London, London, UK[7]Huangshi Central Hospital, Huangshi, Hubei, China[8]Affiliated Taihe Hospital of Hubei University of Medicine,Shiyan, Hubei, China[9]Tongji Hospital, Tongji Medical College, Huazhong University ofScience and Technology, Wuhan, Hubei, China华中科技大学同济医学院附属同济医院[10]China Resources & Wisco general hospital, Wuhan, Hubei, China[11]Wuhan No.1 Hospital, Wuhan, Hubei, China[12]Jingzhou First People’s Hospital, The First Affiliated Hospital ofYangtze University, Jingzhou, Hubei, China[13]Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei,China[14]Peking University People’s Hospital, Peking University Instituteof Hematology, National Clinical Research Center forHematologic Disease, Beijing Key Laboratory of HematopoieticStem Cell Transplantation, Beijing, China
We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.
基金：
Natural Science Foundation of ChinaNational Natural Science Foundation of China [81873440, 81770161, 81700142]; National Institute of Health Research (NIHR) Biomedical Research Centre funding schemeNational Institute for Health Research (NIHR)
医学